This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Genta Takes Another Stab

But this has been a year in which crazy stuff worked, so we'll know soon enough if Genta can add itself to that list.


My BioBuzz item on Opexa Therapeutics (OPXA) perturbed Nicholas, who writes, "Stop hating [Bleep]-hole. You dont [sic] know [Bleep] about Tovaxin or the validity of the data. The data was good. Your [sic] a [Bleeping] political science major, not a medical expert. You dont [sic] know [Bleep] so dont [sic] write 'more of the same' without more evidence and understanding. Your [sic] a loser!!"

I know, Nicholas' spelling needs work, although I'm proud he got "loser" right. (Remember, it's l-o-s-e-r, not l-o-o-s-e-r.)

Judging by his email, I'm not sure I'd want Nicholas to be my go-to expert on Tovaxin either, but his anger was echoed in other emails, all of which accuse me of glossing over the "newness" of Monday's update from the phase II Tovaxin study.

I don't think I did that at all. The point I was making was that Monday's data announcement was "more of the same" about the subgroup of multiple sclerosis patients Opexa cherry-picked out of the failed phase II study from last fall.

I don't see any sensible reason to believe in Tovaxin until the company conducts another randomized and controlled study in these multiple sclerosis patients.

If day traders and momentum investors want to use Opexa as their newest favorite chew toy, then so be it, but please, don't try to base your argument on the strength of the Tovaxin data.

3 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,877.13 -108.48 -0.64%
S&P 500 1,962.01 -10.82 -0.55%
NASDAQ 4,389.9380 -29.0960 -0.66%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs